Sutro Biopharma Q1 2024 Adj EPS $(0.95) Misses $(0.92) Estimate, Sales $13.008M Beat $12.071M Estimate
Portfolio Pulse from Benzinga Newsdesk
Sutro Biopharma reported Q1 2024 earnings with an adjusted EPS of $(0.95), missing the $(0.92) estimate, but sales of $13.008M exceeded the $12.071M forecast, marking a 2.64% increase from the previous year.

May 13, 2024 | 8:41 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Sutro Biopharma's Q1 2024 earnings report showed a miss on EPS estimates but exceeded sales forecasts, indicating mixed financial health.
The miss on the EPS estimate could negatively impact investor sentiment, while the beat on sales forecasts and year-over-year sales growth could counterbalance this with a positive outlook on the company's revenue-generating capability. The mixed financial results make the short-term price direction uncertain, hence a neutral score.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100